Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.46% -0.04% 9.164B 2.548M
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.22% 29.00% 102.47M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Greg Savage 12.76 yrs
Jennifer Hsui 8.17 yrs
Alan Mason 4.47 yrs
Amy Whitelaw 2.17 yrs
Rachel Aguirre 2.17 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 16
102.47M
-4.236B Category Low
3.840B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of September 30, 2020

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of October 26, 2020. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2013
2014
2015
2016
2017
2018
2019
YTD
65.54%
33.83%
11.56%
-21.41%
21.08%
-9.53%
25.21%
12.34%
26.68%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
2.74%
50.56%
47.55%
10.90%
-19.59%
37.07%
-0.30%
19.74%
4.44%
47.61%
25.42%
0.27%
-5.21%
21.82%
-1.33%
22.26%
17.51%
--
--
19.54%
6.26%
24.07%
-13.95%
24.73%
13.14%
159.6%
66.79%
13.93%
-44.17%
40.49%
-24.93%
46.71%
12.34%
As of October 26, 2020.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (10-27-20) 0.22%
30-Day SEC Yield (3-31-20) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of October 23, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of October 23, 2020

Asset Allocation

As of October 23, 2020.
Type % Net % Long % Short
Cash 1.18% Upgrade Upgrade
Stock 98.82% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Gilead Sciences Inc 7.39% 59.86 -0.17%
Amgen Inc 7.28% 222.22 -1.19%
Regeneron Pharmaceuticals Inc 6.36% 582.00 -0.64%
Vertex Pharmaceuticals Inc 5.78% 212.19 2.43%
Illumina Inc 4.95% 323.00 1.23%
Biogen Inc 3.74% 255.00 -0.69%
Seagen Inc Ordinary Shares 3.64% 196.94 0.57%
Moderna Inc 2.95% 70.49 0.36%
Alexion Pharmaceuticals Inc 2.83% 119.93 -0.69%
Incyte Corp 2.08% 88.27 -2.40%

Basic Info

Investment Strategy
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Greg Savage 12.76 yrs
Jennifer Hsui 8.17 yrs
Alan Mason 4.47 yrs
Amy Whitelaw 2.17 yrs
Rachel Aguirre 2.17 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (10-27-20) 0.22%
30-Day SEC Yield (3-31-20) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of October 23, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of October 23, 2020

Fund Details

Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2020
Last Prospectus Date 8/17/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
Socially Responsible Fund No